top of page
What's the Latest
PFCD Statement on Mandatory Medicare Demos Implementing Most Favored Nation Drug Pricing
December 19, 2025 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement today in response to the Centers for Medicare and Medicaid Services (CMS) announcement of mandatory demonstration projects that would implement Most Favored Nation (MFN) drug pricing in Medicare Parts B and D: “PFCD remains opposed to a MFN approach to drug price-setting that would import foreign price controls, threaten patient access, pose ethical concerns,
Dec 19, 2025
New Report: Chronic Disease Could Cost the U.S. $47 Trillion Over Next 15 Years
Multiple Chronic Conditions a Key Driver of Unsustainable Spending Growth December 18, 2025 (Washington, D.C.) New national and state data released today by the Partnership to Fight Chronic Disease (PFCD) projects that chronic disease is on pace to cost the United States as much as $47 trillion between 2024 and 2039, including $2.2 trillion annually in medical costs and nearly $900 billion each year in lost productivity by 2039 . The analysis, conducted by GlobalData, highli
Dec 18, 2025
PFCD Applauds Senate Action on PBMs
December 5, 2025 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the introduction of the Pharmacy Benefit Manager (PBM) Price Transparency and Accountability Act: “The Partnership to Fight Chronic Disease (PFCD) applauds Senate Finance Committee Chairman Mike Crapo and Ranking Member Ron Wyden for introducing the bipartisan Pharmacy Benefit Manager (PBM) Price Transparency and Accountability Act , which aim
Dec 5, 2025
Why PBM Reform, not MFN, is a Viable Path to Affordable Drug Access
More than half of American adults manage multiple chronic conditions . The prevalence is enough to strain the U.S. healthcare system and challenge patient access to new treatments. To compound the issue, pharmacy benefit managers (PBMs) and others siphon nearly half of every dollar spent on brand-name drugs, driving up costs for patients. Reform for how Americans access drugs is a primary topic in Washington. Of the two trending options on the table, only one puts patients fi
Dec 4, 2025
Getting to the Heart of the Matter: Maternal Health Challenges for Black Women Imperative to Fight Against Chronic Disease
Becoming a new mother is often described as one of life’s most extraordinary experiences. Yet for many women, the period following childbirth is also marked by profound physical, emotional, and systemic challenges. As chronic diseases become increasingly common contributors to maternal complications and mortality, understanding and addressing the broader social determinants of health is essential to addressing the realities, especially those facing Black mothers and their bab
Dec 1, 2025
PFCD Responds on IPAY 2027 and Impacts for People Living with Chronic Disease
November 26, 2025 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) announcement of the “maximum fair prices” for the 15 drugs selected for Medicare price-setting in 2027 under the Inflation Reduction Act (IRA): “Nearly 88% of U.S. adults aged 65+ rely on prescription medicines monthly, with 40% using five or more. When considering how best to improve overal
Nov 25, 2025
bottom of page